EXT1 and breast carcinoma: Kaplan–Meier analysis showed that the overall survival rates were significantly lower in breast cancer patients with than without amplification of one of these genes (log rank test; NDRG1, P = 0.0554; UBR5, P = 0.0122; MYC, P = 0.0094; EXT1, P = 0.0103; NBN, P = 0.0030; and COX6C, P = 0.0073) (Figure 4B).